Explore All Access
Check if your research matches the topics covered in Cancer Treatment and Research Communications?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Cancer Treatment and Research Communications : Impact Factor & More
eISSN: 2468-2942
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Cancer Treatment and Research Communications Key Metrics
CiteScore 
1
SJR
Q4Oncology
Time to Accept
2
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months54%
4 to 6 months29%
7 to 9 months7%
Above 9 months10%
Did you find this useful?
Topics Covered on Cancer Treatment and Research Communications
Cancer
Lung cancer
Resveratrol
Adjuvant
Cancer development
Muscle damage
Fever of unknown origin
Osteosarcoma
Progression-free survival
Breast cancer
Tumor microenvironment
Multivariate analysis
Immune checkpoint
Overall survival
Toxicity
Temozolomide
Prostate cancer
Stage iiib
Platinum
Gene expression
Cancer Treatment and Research Communications Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | USD 1650 |
| Publication Time | 17 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Language | English |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Cancer Treatment and Research Communications ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Treatment and Research Communications
The Prevalence and Prognostic Significance of Sarcopenia and Adipopenia in Pleural Mesothelioma
- 1 Dec 2024
- Cancer Treatment and Research Communications
Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era
- 1 Nov 2024
- Cancer Treatment and Research Communications
A risk stratification model for predicting chemotherapy benefit in breast neuroendocrine carcinoma: A population-based analysis
- 1 Nov 2024
- Cancer Treatment and Research Communications
Characterization of genomic profiling of Mexican women with breast cancer using Endopredict
- 1 Nov 2024
- Cancer Treatment and Research Communications
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
- 1 Sep 2024
- Cancer Treatment and Research Communications
Low to intermediate grade lung neuroendocrine tumours. A single centre real world experience
- 1 Sep 2024
- Cancer Treatment and Research Communications
The Prevalence and Prognostic Significance of Sarcopenia and Adipopenia in Pleural Mesothelioma
- 1 Dec 2024
- Cancer Treatment and Research Communications
Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era
- 1 Nov 2024
- Cancer Treatment and Research Communications
A risk stratification model for predicting chemotherapy benefit in breast neuroendocrine carcinoma: A population-based analysis
- 1 Nov 2024
- Cancer Treatment and Research Communications
Characterization of genomic profiling of Mexican women with breast cancer using Endopredict
- 1 Nov 2024
- Cancer Treatment and Research Communications
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
- 1 Sep 2024
- Cancer Treatment and Research Communications
Low to intermediate grade lung neuroendocrine tumours. A single centre real world experience
- 1 Sep 2024
- Cancer Treatment and Research Communications
Compare Similar Journals with Cancer Treatment and Research Communications
Select Journals to Compare with Cancer Treatment and Research Communications
Total journals - 9
You can select up to 3 Journals at a time
Annals of Oncology
Publisher: ELSEVIER
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
BMC Cancer
Publisher: BMC
Oncotarget
Publisher: Impact Journals
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
Journal of Thoracic Oncology
Publisher: ELSEVIER SCIENCE INC
0 Journals Selected to compare with
Cancer Treatment and Research Communications
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Cancer Treatment and Research Communications
How many articles did Cancer Treatment and Research Communications publish last year? 
In 2023, Cancer Treatment and Research Communications publsihed 102 articles.
What is Citescore for Cancer Treatment and Research Communications?
Citescore for Cancer Treatment and Research Communications is 1.
What is the SJR for Cancer Treatment and Research Communications?
SJR for Cancer Treatment and Research Communications is Q4.
Who is the publisher of Cancer Treatment and Research Communications?
Elsevier is the publisher of Cancer Treatment and Research Communications.
